Dihexasafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Dihexa as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Dihexa is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Dihexa's safety dataset is limited to pre-clinical work — there are no published human clinical-trial data. The pre-clinical safety record across rodent cognitive and pharmacology studies has been favourable: oral and parenteral doses over the research dose range have produced no overt toxicity, no significant changes in routine haematology or hepatic enzymes, and no organ-specific lesions in standard histopathology. Acute toxicology has not identified dose-limiting adverse effects at doses substantially above the cognitive-efficacy range. Theoretical safety considerations centre on the HGF/c-Met pathway's broader biological roles. HGF/c-Met signalling is critical in tissue regeneration but is also implicated in tumour growth and metastasis in several cancer contexts — HGF/c-Met inhibitors are oncology development targets (cabozantinib, tepotinib, capmatinib), reflecting the role of c-Met activation in cancer biology. Pharmacological potentiation of HGF/c-Met signalling could theoretically promote tumour growth in subjects with occult or recent malignancy. This theoretical concern has not been substantiated in pre-clinical Dihexa studies, but the chronic-dosing oncology safety profile in humans is uncharacterised. Additional theoretical considerations include the broader effects of HGF/c-Met activation on non-CNS tissues (liver regeneration is the original HGF context — the protein was first characterised as a hepatic regeneration factor). Chronic HGF/c-Met potentiation could theoretically affect hepatic, renal, and pulmonary tissue dynamics in ways not characterised at research-dose tiers. The peptide's hexapeptide architecture with N-terminal hexanoyl modification carries low immunogenicity risk. Anti-drug antibodies have not been a documented issue in the pre-clinical work. No serious adverse events have been reported in any published Dihexa research. The acute and sub-chronic safety profile in research animals is favourable; the chronic-dosing and human safety record is absent.

UK regulatory status

Dihexa is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Research-grade material is available from research-chemical suppliers for legitimate pre-clinical and academic research use; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration of Dihexa to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. Dihexa is not currently on the WADA Prohibited List. The compound's mechanism (HGF/c-Met potentiation, cognitive enhancement) does not currently fall within any WADA category, though athletes should verify the current annual Prohibited List as classifications can change with emerging compounds. For animal research under ASPA, Dihexa work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit. There is no current UK clinical-research infrastructure for Dihexa. Research-chemical-community use exists but lacks the pharmacokinetic, toxicology, and efficacy framework that would support evidence-based human dosing.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Dihexa is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Dihexa research context including mechanism, study citations, and references, see the main Dihexa research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.